Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
NCT ID: NCT01848899
Last Updated: 2016-04-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
100 participants
INTERVENTIONAL
2013-02-28
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anticoagulation in Post MI LV Thrombus Trial in Nepal
NCT05794399
Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography
NCT02103959
MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction
NCT01319760
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
NCT02404376
Rivaroxaban in Type 2 Myocardial Infarctions
NCT04838808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ioxaglate Arm
Ioxaglate
contrast media used during coronary angiography
Bivalirudin
A direct thrombin inhibitor
Iodixanol arm
Iodixanol
contrast media used during coronary angiography
Bivalirudin
A direct thrombin inhibitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iodixanol
contrast media used during coronary angiography
Ioxaglate
contrast media used during coronary angiography
Bivalirudin
A direct thrombin inhibitor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* referred for coronary angiography and on dual anti-platelet therapy (aspirin and clopidogrel).
Exclusion Criteria
* on low molecular weight heparin within 12 hours of coronary angiography or unfractionated heparin with activated clotting time \>150 at time of procedure -on cilostazol
* on persantine
* on non- steroidal anti-inflammatory medications (ibuprofen/motrin/advil, naproxen/aleve, indomethacin, sulindac, etodolac, diclofenac, celecoxib) within 72 hours of procedure
* undergoing coronary angiography via radial access
* undergoing planned diagnostic coronary angiography only
* unable to tolerate dual anti-platelet therapy
* with known allergy to CM
* received CM within 24 hours of coronary angiography
* on dialysis
* do not consent or are unable to give consent
* are participating in another competing study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guerbet
INDUSTRY
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fred Feit, MD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Binita Shah, MD, MS
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York University School of Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-02409
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.